These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 36853587)

  • 1. Management of Older Adults with Sickle Cell Disease: Considerations for Current and Emerging Therapies.
    Oyedeji CI; Hodulik KL; Telen MJ; Strouse JJ
    Drugs Aging; 2023 Apr; 40(4):317-334. PubMed ID: 36853587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Fortin PM; Bull KR; Doree C; Trivella M; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012380. PubMed ID: 28672087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folate supplementation in people with sickle cell disease.
    Dixit R; Nettem S; Madan SS; Soe HHK; Abas AB; Vance LD; Stover PJ
    Cochrane Database Syst Rev; 2018 Mar; 3(3):CD011130. PubMed ID: 29546732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
    Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
    JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions for chronic kidney disease in people with sickle cell disease.
    Roy NB; Carpenter A; Dale-Harris I; Dorée C; Estcourt LJ
    Cochrane Database Syst Rev; 2023 Aug; 8(8):CD012380. PubMed ID: 37539955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic: A Qualitative Study.
    Sinha CB; Bakshi N; Ross D; Krishnamurti L
    JAMA Netw Open; 2019 May; 2(5):e194410. PubMed ID: 31125105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surveillance for Sickle Cell Disease - Sickle Cell Data Collection Program, Two States, 2004-2018.
    Snyder AB; Lakshmanan S; Hulihan MM; Paulukonis ST; Zhou M; Horiuchi SS; Abe K; Pope SN; Schieve LA
    MMWR Surveill Summ; 2022 Oct; 71(9):1-18. PubMed ID: 36201430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red blood cell transfusion to treat or prevent complications in sickle cell disease: an overview of Cochrane reviews.
    Fortin PM; Hopewell S; Estcourt LJ
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012082. PubMed ID: 30067867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea for children with sickle cell disease in sub-Saharan Africa: A summary of the evidence, opportunities, and challenges.
    Dexter D; McGann PT
    Pharmacotherapy; 2023 May; 43(5):430-441. PubMed ID: 36906823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative blood transfusions for sickle cell disease.
    Estcourt LJ; Kimber C; Trivella M; Doree C; Hopewell S
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD003149. PubMed ID: 32614473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea (hydroxycarbamide) for sickle cell disease.
    Rankine-Mullings AE; Nevitt SJ
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD002202. PubMed ID: 36047926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations.
    Obadina M; Wilson S; Derebail VK; Little J
    Kidney360; 2023 Jul; 4(7):997-1005. PubMed ID: 37254256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How we prevent and manage infection in sickle cell disease.
    Sobota A; Sabharwal V; Fonebi G; Steinberg M
    Br J Haematol; 2015 Sep; 170(6):757-67. PubMed ID: 26018640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic penicillin after 5 years of age in patients with sickle cell disease: a survey of sickle cell disease experts.
    McCavit TL; Gilbert M; Buchanan GR
    Pediatr Blood Cancer; 2013 Jun; 60(6):935-9. PubMed ID: 23193095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapies in sickle cell disease.
    Nardo-Marino A; Brousse V; Rees D
    Br J Haematol; 2020 Jul; 190(2):149-172. PubMed ID: 32142156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging drugs for the treatment of sickle cell disease: a review of phase II/III trials.
    Ross JM; Forté S; Soulières D
    Expert Opin Emerg Drugs; 2022 Jun; 27(2):211-224. PubMed ID: 35912835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-related prescription medication utilization for the -management of sickle cell disease among Texas Medicaid patients.
    Shukla N; Barner JC; Lawson KA; Rascati KL
    J Opioid Manag; 2021; 17(4):301-310. PubMed ID: 34533824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Therapies for the Management of Sickle Cell Disease.
    Rai P; Ataga KI
    F1000Res; 2020; 9():. PubMed ID: 32765834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Effectiveness of Common Interventions in the Management of Sickle Cell Disease in Primary Care Settings: A Review.
    Mbaezue RN; Okafor AT; Nkwocha BI; Ibeneme CN; Opara AC; Akahara DE; Okobi OE
    Cureus; 2023 Sep; 15(9):e44780. PubMed ID: 37809245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.